Login to Your Account



'Affinitak Phase III Failure Bump In Road,' Says Isis

By Randall Osborne


Tuesday, March 18, 2003
Shares of Isis Pharmaceuticals Inc. fell 31.9 percent after the company disclosed data from the first of two Phase III studies with Affinitak, showing the antisense drug partnered with Eli Lilly and Co. failed to meet its primary endpoint. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription